Photosensitizers in clinical PDT
Photosensitizers in clinical PDT
复制标题
DOI：
10.1016/s1572-1000(04)00007-9
复制
发表时间：
2004-05-01
影响因子：
3.3
通讯作者：
Sibata, Claudio H.
中科院分区：
文献类型：
--
作者：
Allison, Ron R.;Downie, Gordon H.;Sibata, Claudio H.
光动力疗法中的光敏剂允许将光能转移和转化为第二类化学反应。在临床实践中，光敏剂有三个家族--卟啉、叶绿素和染料。所有临床上成功的光敏剂都有或多或少的能力，以特定的组织或其血管系统为靶点，实现消融。每种光敏剂都需要在对治疗有用的足够高的光波长下可靠地激活。他们的荧光和可视化病变的能力是一个额外的好处。从每个家族开发的光敏剂都有独特的特性，到目前为止还没有在临床上得到最小限度的开发。这篇综述着眼于已在临床环境中尝试的每种主要光敏剂的潜在好处和后果。(C)2004爱思唯尔B.V.保留所有权利。
Photosensitizers in photodynamic therapy allow for the transfer and translation of light energy into a type II chemical reaction. In clinical practice, photosensitizers arise from three families-porphyrins, chlorophylls, and dyes. All clinically successful photosensitizers have the ability to a greater or lesser degree, to target specific tissues or their vasculature to achieve ablation. Each photosensitizer needs to reliably activate at a high enough light wavelength useful for therapy. Their ability to fluoresce and visualize the lesion is a bonus. Photosensitizers developed from each family have unique properties that have so far been minimally clinically exploited. This review looks at the potential benefits and consequences of each major photosensitizer that has been tried in a clinical setting. (C) 2004 Elsevier B.V. All rights reserved.